Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.
The allogeneic transplant of haematopoietic cell is the only treatment option for many malignant blood diseases. Unfortunately, the progression free survival and the quality of life of transplanted patients is limited due to the development of graft-versus-host-disease (GVHD).
The development of new prophylaxis strategies of GVHD based in the use of immunomodulator agents (allowing the generation of an immunotolerance state and avoiding the use of immunosuppression) is essential.
The GVHD is due to the cytotoxic effect of the donor lymphocytes T against healthy organs and tissues of the receptor. Calcineurin inhibitor combined with methotrexate or antibodies anti-lymphocytes T are used as standard prophylaxis. This type of antibodies has demonstrated efficacy to reduce GVHD, but have not increased survival due to increasing the risk of relapses and serious post-transplant infections.
Due to its interactions with VDR (vitamin D receptor) present in immune system cells, vitamin D is able to inhibit the activation of dendritic cells and the proliferation and production of cytokines by lymphocytes T. Based on this effect, the peri- and post- transplant administration of vitamin D might decrease the risk of GVHD in allogeneic transplanted patients, subsequently decreasing the immunosuppressant treatment requirements and improving the prognosis of those patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1: Control | No Intervention | Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups. | |
| Group 2: 1000IU/day of Vitamine D | Experimental | It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day. |
|
| Group 3: 5000IU/day of Vitamine D | Experimental | It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 1000IU/day of Vitamine D | Drug | Administration of a specified dose of Vitamine D |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence/severity of Graft-Versus-Host-Disease | Number of cases of GVHD/Seriousness graded according to National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease | Day +150 post-transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Serum levels of Th1/Th2 cytokines | (IL-2, IL-4, IL-6, IL-10, tumor necrosis factor alfa (TNF)-α and interferon gamma (IFN-g)) are determined by flow cytometry using the BD Human Th1/Th2 Cytokine CBA | Day -5 pre-transplant and +1, +7, +21,+56 and +100 post-transplant |
| Dendritic cells |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José Antonio Pérez-Simón, MD-PhD | Head of haematology department | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Christelle Ferrà i Coll | Badalona | Barcelona | Spain | |||
| Carmen Martínez |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31043390 | Derived | Carrillo-Cruz E, Garcia-Lozano JR, Marquez-Malaver FJ, Sanchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcarcel D, Lopez-Godino O, Cuesta M, Parody R, Lopez-Corral L, Alcoceba M, Caballero-Velazquez T, Rodriguez-Gil A, Bejarano-Garcia JA, Ramos TL, Perez-Simon JA. Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1. | |
| 27358490 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006086 | Graft vs Host Disease |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5000IU/day of Vitamine D | Drug | Administration of a specified dose of Vitamine D |
|
|
The following markers were used to identify different subpopulations CD16-PB, CD45-V500, HLADR-FITC, BDCA-PE, CD11c-PerCP-Cy5.5, CD86-PE-Cy7, CD123-APC and CD14-APC-H7. Plasmacytoid dendritic cells: HLADR+ CD123++ CD11c- CD16- CD14- BDCA1- CD45+. Monocyte-derived dendritic cells: HLADR+ CD123+d CD11c+ CD16++ CD14-/+d BDCA- CD45+. Myeloid BDCA1 dendritic cells : HLADR+ CD123- CD11c+ CD16- CD14- BDCA+ CD45+ |
| Day +21,+56 and +100 post-transplant |
| Subpopulations of lymphocytes | To be identified using the combination CD19+CD8-FITC, CD3+CD56-PE, CD4- PerCP-Cy5.5, HLADR-APC T cells: CD3+ (CD3+CD4+CD8-, CD3+CD4-CD8+, CD3+CD4+CD8+, CD3+CD4-CD8+) B cells: CD19+ HLADR+ NK cells: CD3- CD19- CD56+ CD45RA-FITC and CCR7-PE were used to distinguish the repertory of naive/effector/memory of CD4 and CD8 cells. -naive T cells: CD45RA+CCR7+ -effector T cells: CD45RA+CCR7- -central memory T cells: CD45RA-CCR7+ -Peripheral memory T cells: CD45RA-CCR7- | Day +21,+56 and +100 post-transplant |
| Regulatory T cells | after incubation of surface antigens (CD25-FITC, CD127-PE and CD4-PerCP-Cy5.5), cells were washed in PBS and then fixed and permeabilized with FoxP3 Staining Buffer Set (eBiosciences) for FOXP3 staining. phenotype of Treg: CD4+CD25+CD127-/+wFoxP3+ | Day +21,+56 and +100 post-transplant |
| NK markers | using the following combinations: CD94-FITC/CD56-PE/CD3-PerCP-Cy5.5/HLADR-APC CD11a-FITC/CD16-PE/CD3-PerCP-Cy5.5/CD56-APC CD158a-FITC/CD161-PE/CD3-PerCP-Cy5.5/CD56-APC CDNKB1-FITC/NKAT-PE/CD3-PerCP-Cy5.5/CD56-APC We identify NK cells with weak expression of CD56 (CD56 called " weak) and those expressing more intensely this marker CD56 "bright ". In addition the expression of different KIR receptor as CD158a , CD161 , and NKAT2 NKB1 were reported. | Day +21,+56 and +100 post-transplant |
| Activation of T cells | Activation assays are performed on 500 µl of peripheral blood added in 48-well plates. Peripheral blood is stimulated or not with PMA (20µg/2ml) and ionomycin (0.91 µg/ml). | Day +21,+56 and +100 post-transplant |
| Peak Plasma Concentration (Cmax) of Vitamin D | Peak Plasma Concentration (Cmax) | Day -5 pre-transplant and +1, +7 and +21 post-transplant |
| Area under the plasma concentration of Vitamin D | Area under the plasma concentration versus time curve (AUC) | Day -5 pre-transplant and +1, +7 and +21 post-transplant |
| Bone densitometry changes carried out by protocol in post-transplant period | Treatment effect in the subsequent development of osteoporosis | Day +150 post-transplant |
| Barcelona |
| Barcelona |
| Spain |
| David Valcárcel Ferreiras | Barcelona | Barcelona | Spain |
| Raquel Saldaña Moreno | Jerez de la Frontera | Cádiz | Spain |
| Manuel Jurado Chacón | Granada | Granada | Spain |
| Mª Ángeles Cuesta | Málaga | Málaga | Spain |
| Fermín Martín Sánchez- Guijo | Salamanca | Salamanca | Spain |
| Derived |
| Caballero-Velazquez T, Montero I, Sanchez-Guijo F, Parody R, Saldana R, Valcarcel D, Lopez-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sanchez-Abarca LI, Lopez-Corral L, Marquez-Malaver FJ, Perez-Simon JA; GETH (Grupo Espanol de Trasplante Hematopoyetico). Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. doi: 10.1158/1078-0432.CCR-16-0238. Epub 2016 Jun 29. |